Source Count: 16 | Weighted Score: 40 | Source Confidence: [4/5] | Primary Tier: 1 | Last Updated: 2026-03-13 11, 2026
Keywords: proteomics, mass spectrometry, protein identification, two-dimensional gel electrophoresis, tandem MS, post-translational modification, proteome, shotgun proteomics, quantitative
Category Tags: molecular-biology, biochemistry, omics, analytical-chemistry, systems-biology
Cross-References: Z_5_03 — Metabolomics · Z_4_09 — Protein Folding · Z_5_08 — DNA

QUICK SUMMARY

Proteomics — the large-scale study of the complete set of proteins (proteome) expressed by a cell, tissue, or organism at a given time — bridges the gap between the genome (static DNA sequence) and the phenotype (observable characteristics) by characterizing the actual molecular effectors of biological function. While the human genome encodes ~20,000 protein-coding genes, the human proteome is vastly more complex — alternative splicing, post-translational modifications (PTMs — phosphorylation, glycosylation, ubiquitination, acetylation, etc.), proteolytic processing, and protein-protein interactions generate an estimated >1 million distinct proteoforms. The term "proteome" was coined by Marc Wilkins in 1994 (as a deliberate parallel to "genome"), and the field has been primarily driven by advances in mass spectrometry (MS) — particularly electrospray ionization (John Fenn, Nobel Prize 2002) and matrix-assisted laser desorption/ionization (Koichi Tanaka, Nobel Prize 2002). Modern "shotgun" proteomics (LC-MS/MS) can identify and quantify >10,000 proteins from a single cell lysate in a few hours, while targeted approaches (selected reaction monitoring — SRM/MRM) provide precise quantification of specific proteins across thousands of samples. Proteomics has transformed biology by enabling the global characterization of protein expression (expression proteomics), protein-protein interactions (interactomics), post-translational modifications (PTM proteomics, especially phosphoproteomics), and protein localization — with major applications in cancer biomarker discovery, drug target identification, and understanding cellular signaling networks.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Established)

1.1 Analytical Platforms

• Two-dimensional gel electrophoresis (2D-GE): the original proteomics technology — separates proteins by isoelectric point (first dimension) and molecular weight (second dimension); can resolve ~2,000 protein spots per gel; largely supplanted by MS-based methods for large-scale analysis but still used for specific applications
• Tandem mass spectrometry (MS/MS): the dominant technology — proteins are digested into peptides by trypsin → peptides are separated by liquid chromatography (LC) → ionized by electrospray (ESI) → fragmented in the mass spectrometer → fragment ion patterns identify the peptide sequence; database search algorithms (SEQUEST, Mascot, MaxQuant) match spectra to peptide sequences
• Ionization methods: electrospray ionization (ESI — Fenn, Nobel 2002) and MALDI (matrix-assisted laser desorption/ionization — Tanaka, Nobel 2002) enabled the mass spectrometric analysis of large biomolecules without fragmentation

1.2 Quantitative Proteomics

• Label-free quantification: comparing ion signal intensities (peak areas or spectral counts) across samples
• Isotopic labeling: SILAC (stable isotope labeling by amino acids in cell culture — Ong et al., 2002), TMT/iTRAQ (chemical labeling for multiplexed quantification — up to 18 samples simultaneously)
• Targeted quantification: SRM/MRM (selected/multiple reaction monitoring) — monitors specific peptide transitions with high precision and sensitivity; considered the "gold standard" for protein quantification; analogous to Western blot but multiplexed and quantitative

1.3 Major Proteomics Resources

• UniProt: comprehensive protein sequence database with functional annotation (~250 million sequences, ~570,000 manually curated)
• Human Proteome Project (HPP): international initiative to systematically identify all human proteins — as of 2024, >18,000 of ~20,000 predicted proteins have been identified by MS with high confidence (PE1 — protein-level evidence)
• ProteomeXchange/PRIDE: public repositories for proteomics data

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Phosphoproteomics and Signaling

• Phosphoproteomics: the global study of protein phosphorylation using enrichment strategies (TiO₂, IMAC) coupled to LC-MS/MS; >100,000 phosphorylation sites have been mapped in the human proteome
• Enables monitoring of signaling pathway activation at global scale — tracking thousands of phosphorylation events simultaneously in response to stimuli, drugs, or disease states; critical for understanding kinase signaling networks and identifying drug targets

2.2 Single-Cell Proteomics

• Emerging technology — recent advances (SCoPE-MS, Slavov lab; plexDIA) enable quantification of ~1,000–3,000 proteins from individual cells; this addresses a fundamental limitation of bulk proteomics (which averages signal across millions of cells, masking cell-to-cell heterogeneity)
• Single-cell proteomics is expected to complement single-cell genomics and transcriptomics, providing a more complete picture of cellular identity and state

2.3 Clinical Proteomics and Biomarkers

• Blood-based proteomic profiling (SomaScan — aptamer-based; Olink — proximity extension assay) can now measure ~5,000–7,000 proteins from small blood samples; large-scale epidemiological studies using these platforms have identified proteomic signatures associated with cardiovascular disease, diabetes, cancer, and aging

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Complete Proteoform Catalog

• The goal of mapping all proteoforms (including all splice variants, PTMs, and protein complexes) in all human cell types under all conditions remains aspirational — the combinatorial complexity is enormous, and current technology captures only a fraction of the total proteoform diversity

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 Proteomics Replaces Genomics

• [OVERSIMPLIFIED] Claims that proteomics will replace genomics and transcriptomics — each "-omics" level provides complementary information; protein levels are only partly predicted by mRNA levels; all levels of analysis are needed for a complete understanding of biological systems

COUNTER-ARGUMENTS & CRITICISMS

1. Proteomics Suffers from Fundamental Reproducibility Problems

Bell et al. (2009, "A HUPO Test Sample Study Reveals Common Problems in Mass Spectrometry-Based Proteomics," Nature Methods 6(6): 423–430, DOI: 10.1038/nmeth.1333) found that different laboratories analyzing identical samples identified substantially different protein sets, with overlap as low as ~50%. Tabb (2013, "Quality Assessment for Clinical Proteomics," Clinical Biochemistry 46(10–11): 879–884) documented that peptide identification algorithms produce different results depending on parameter settings, raising concerns about the robustness of proteomic datasets.

2. The "Dark Proteome" Problem Undermines Completeness Claims

Perdigao et al. (2015, "Unexpected Features of the Dark Proteome," PNAS 112(52): 15898–15903, DOI: 10.1073/pnas.1508380112) estimated that ~44% of the human proteome consists of "dark proteins" with unknown structure and function — calling into question claims about comprehensive proteome characterization. Many predicted protein-coding genes may not produce stable proteins in vivo.

3. Mass Spectrometry Bias Against Low-Abundance Proteins Limits Clinical Utility

Anderson and Anderson (2002, "The Human Plasma Proteome: History, Character, and Diagnostic Prospects," Molecular & Cellular Proteomics 1(11): 845–867, DOI: 10.1074/mcp.R200007-MCP200) demonstrated that plasma proteins span a concentration range of >10 orders of magnitude, with high-abundance proteins (albumin, immunoglobulins) dominating detection. Disease biomarkers typically exist at low concentrations, precisely where mass spectrometry performs worst.

4. Post-Translational Modification Coverage Remains Inadequate

Olsen and Mann (2013, "Status of Large-Scale Analysis of Post-Translational Modifications by Mass Spectrometry," Molecular & Cellular Proteomics 12(12): 3444–3452, DOI: 10.1074/mcp.O113.034181) noted that despite advances, comprehensive PTM analysis remains technically challenging — many modifications are labile, low-stoichiometry, or lost during sample preparation, meaning the actual functional proteome is substantially more complex than current methods can capture.

5. Single-Cell Proteomics Faces Fundamental Sensitivity Limitations

Kelly (2020, "Single-Cell Proteomics: Progress and Prospects," Molecular & Cellular Proteomics 19(5): 739–748, DOI: 10.1074/mcp.R120.002076) acknowledges that unlike single-cell genomics (which benefits from nucleic acid amplification), proteins cannot be amplified — creating a fundamental sensitivity barrier. Current single-cell proteomics captures only ~1,000-3,000 proteins per cell versus the estimated ~10,000-20,000 expressed, missing low-abundance regulatory proteins critical for understanding cellular function.

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Aebersold, Ruedi; Matthias Mann | 2016 | "Mass-Spectrometric Exploration of Proteome Structure and Function" | Nature | ∅ | 537::347–355 | ∅ | ∅ | doi:10.1038/nature19949 | ∅ | ∅ | ∅
2. Wilkins, Marc R., et al | 1996 | "Progress with Proteome Projects" | Biotechnology and Genetic Engineering Reviews | ∅ | 13::19–50 | ∅ | ∅ | doi:10.1080/02648725.1996.10647923 | ∅ | ∅ | ∅
3. Fenn, John B., et al | 1989 | "Electrospray Ionization for Mass Spectrometry of Large Biomolecules" | Science | ∅ | 246.4926::64–71 | ∅ | ∅ | doi:10.1126/science.2675315 | ∅ | ∅ | ∅
4. Ong, Shao-En, et al | 2002 | "SILAC as a Simple and Accurate Approach to Expression Proteomics" | Molecular & Cellular Proteomics | ∅ | 1.5::376–386 | ∅ | ∅ | doi:10.1074/mcp.M200025-MCP200 | ∅ | ∅ | ∅
5. Cox, Jürgen; Matthias Mann | 2008 | "MaxQuant Enables High Peptide Identification Rates" | Nature Biotechnology | ∅ | 26.12::1367–1372 | ∅ | ∅ | doi:10.1038/nbt.1511 | ∅ | ∅ | ∅
6. Omenn, Gilbert S., et al | 2021 | "Progress on Identifying and Characterizing the Human Proteome" | Journal of Proteome Research | ∅ | 20.1::330–340 | ∅ | ∅ | doi:10.1021/acs.jproteome.0c00550 | ∅ | ∅ | ∅
7. Slavov, Nikolai | 2021 | "Single-Cell Protein Analysis by Mass Spectrometry" | Current Opinion in Chemical Biology | ∅ | 60::1–9 | ∅ | ∅ | doi:10.1016/j.cbpa.2020.04.018 | ∅ | ∅ | ∅
8. Sun, Bryan B., et al | 2018 | "Genomic Atlas of the Human Plasma Proteome" | Nature | ∅ | 558::73–79 | ∅ | ∅ | doi:10.1038/s41586-018-0175-2 | ∅ | ∅ | ∅
9. Bell, Alexander W., et al | 2009 | "A HUPO Test Sample Study Reveals Common Problems in Mass Spectrometry-Based Proteomics" | Nature Methods | ∅ | 6.6::423–430 | ∅ | ∅ | doi:10.1038/nmeth.1333 | ∅ | ∅ | ∅
10. Tabb, David L | 2013 | "Quality Assessment for Clinical Proteomics" | Clinical Biochemistry | ∅ | 11::879–884 | 46.10 | ∅ | doi:10.1016/j.clinbiochem.2012.12.003 | ∅ | ∅ | ∅
11. Perdigao, Nelson, et al | 2015 | "Unexpected Features of the Dark Proteome" | PNAS | ∅ | 112.52::15898–15903 | ∅ | ∅ | doi:10.1073/pnas.1508380112 | ∅ | ∅ | ∅
12. Anderson, N | 2002 | "The Human Plasma Proteome" | Molecular & Cellular Proteomics | ∅ | 1.11::845–867 | Leigh, and Norman G | ∅ | doi:10.1074/mcp.R200007-MCP200 | ∅ | ∅ | Anderson
13. Olsen, Jesper V.; Matthias Mann | 2013 | "Status of Large-Scale Analysis of Post-Translational Modifications" | Molecular & Cellular Proteomics | ∅ | 12.12::3444–3452 | ∅ | ∅ | doi:10.1074/mcp.O113.034181 | ∅ | ∅ | ∅
14. Kelly, Ryan T | 2020 | "Single-Cell Proteomics: Progress and Prospects" | Molecular & Cellular Proteomics | ∅ | 19.5::739–748 | ∅ | ∅ | doi:10.1074/mcp.R120.002076 | ∅ | ∅ | ∅
15. Bantscheff, Marcus, et al | 2007 | "Quantitative Mass Spectrometry in Proteomics: A Critical Review" | Analytical and Bioanalytical Chemistry | ∅ | 389.4::1017–1031 | ∅ | ∅ | doi:10.1007/s00216-007-1486-6 | ∅ | ∅ | ∅
16. Mann, Matthias | 2014 | ∅ | Fifteen Years of Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) | ∅ | ∅ | Springer New York | ∅ | doi:10.1007/978-1-4939-1142-4_1 | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Generated from V4 expansion plan. Last Updated: March 11, 2026

<table border="1" cellpadding="12" cellspacing="0" style="border-collapse: collapse; border: 2px solid #888; margin-top: 2em; background: #fafafa;">

<tr><td>

⚠️ AI-Assisted Research Disclaimer

This document was generated and structured with the assistance of AI tools.

While every effort is made to ensure accuracy, AI-assisted content may

contain errors, misattributions, or unintended inaccuracies. **Always

verify claims, dates, and sources independently** before citing or relying

on any information presented here.

• Sources may contain errors. Bibliography entries and cross-references

are checked by automated systems, but mistakes can occur. If something

looks wrong, it may be.

• Speculative and unverified claims are clearly labeled. This project

uses a four-tier evidence system:

• Tier 1 — Verified: Peer-reviewed, established scientific consensus.
• Tier 2 — Credible: Academically supported, debated but grounded.
• Tier 3 — Speculative: Plausible but unverified by mainstream science.
• Tier 4 — Dubious: No credible support or contradicted by evidence.
• This project maps multiple perspectives — not a single truth. Mainstream,

alternative, and skeptical viewpoints are presented side by side for

critical comparison, not endorsement. Inclusion does not imply agreement.

• We are actively improving. Source verification, factuality scoring,

and bibliography enrichment are ongoing. Each revision adds stronger

citations, corrects identified errors, and expands coverage.

📖 For full details on our verification methodology, scoring systems, and

quality metrics, see: Fact-Checking & Verification Systems

Think Openly. Check the sources. Draw your own conclusions.

</td></tr>

</table>